Nintendo (OTCMKTS:NTDOY) versus Clinuvel Pharmaceuticals (OTCMKTS:CLVLY) Financial Contrast

Clinuvel Pharmaceuticals (OTCMKTS:CLVLY) and Nintendo (OTCMKTS:NTDOY) are both consumer discretionary companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Clinuvel Pharmaceuticals and Nintendo’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clinuvel Pharmaceuticals	N/A	N/A	N/A
Nintendo	21.00%	16.11%	12.47%

Earnings & Valuation

This table compares Clinuvel Pharmaceuticals and Nintendo”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clinuvel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Nintendo	$15.37 billion	4.69	$2.80 billion	$0.66	21.21

Nintendo has higher revenue and earnings than Clinuvel Pharmaceuticals.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Clinuvel Pharmaceuticals and Nintendo, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clinuvel Pharmaceuticals	0	0	0	0	0.00
Nintendo	1	4	3	1	2.44

Insider & Institutional Ownership

0.0% of Nintendo shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Nintendo beats Clinuvel Pharmaceuticals on 8 of the 8 factors compared between the two stocks.

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.

About Nintendo

Nintendo Co., Ltd., together with its subsidiaries, develops, manufactures, and sells home entertainment products in Japan, the Americas, Europe, and internationally. It also offers video game platforms, playing cards, Karuta, and other products; and handheld and home console hardware systems and related software. The company was formerly known as Nintendo Playing Card Co., Ltd. and changed its name to Nintendo Co., Ltd. in 1963. Nintendo Co., Ltd. was founded in 1889 and is headquartered in Kyoto, Japan.